Genentech's Dual GLP-1/GIP Agonist Shows Strong Phase II Obesity Results
Event summary
- Genentech’s CT-388, a dual GLP-1/GIP receptor agonist, demonstrated a 22.5% placebo-adjusted weight loss in Phase II trial CT388-103 at 48 weeks.
- The study involved 469 participants with obesity or overweight and at least one weight-related comorbidity.
- 73% of pre-diabetic participants treated with CT-388 at 24mg achieved normal blood glucose levels at week 48.
- Phase III clinical trials (Enith1 and Enith2) are expected to commence this quarter.
The big picture
The obesity treatment market is experiencing explosive growth, driven by rising global obesity rates and increasing demand for effective therapies. Genentech’s CT-388, with its significant weight loss results and favorable safety profile, positions the company to capitalize on this trend and compete with established players like Novo Nordisk and Eli Lilly. The dual GLP-1/GIP mechanism represents a potential advantage over single-target therapies, but Phase III trial results will be crucial to validate this hypothesis.
What we're watching
- Clinical Trial Success
- The success of the upcoming Phase III trials will be critical in determining CT-388’s commercial viability and Genentech’s position in the rapidly growing obesity treatment market.
- Combination Therapy
- The potential for CT-388 to be used in combination with petrelintide will significantly impact its overall market value and Genentech’s obesity pipeline strategy.
- Regulatory Approval
- The speed and outcome of regulatory reviews for CT-388 will dictate the timeline for market entry and influence the competitive landscape within the obesity treatment space.
